News Jury finds Takeda liable for $885m in pay-for-delay lawsuit Takeda is on the hook for $885m damages – which could rise to $2.5bn – in a suit claiming it paid a rival to delay the launch of a generic competitor.
News Novartis agrees $245m settlement over Exforge generics delay Novartis has said it will pay $245 million to resolve civil litigation in the US, which accuses it of a 'pay for delay' scheme involving generics of its high blood pressure therapy Exforge.
Oncology ASCO 2026: Chinese firms take a front seat in oncology, with... Dr Li Mao and Dr Giovanni Selvaggi of Betta Pharmaceuticals and Xcovery Holdings discuss their novel ALK inhibitor and the Chinese biotech landscape.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.